Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© Springer-Verlag Berlin Heidelberg 2014. The core of the clinical syndrome of amyotrophic lateral sclerosis (ALS) is a progressive and typically rapid degeneration of a previously normally functioning motor system, comprising upper motor neurons (UMNs) of the primary motor cortex and corticospinal tract (CST), brainstem nuclei and the lower motor neurons (LMNs) arising from the anterior horns of the spinal cord. Weakness, with variable wasting, of the musculature of the limbs and of speech and swallowing ensues, with involvement of the diaphragm resulting in respiratory insuffi ciency and a median survival of 3 years. The marked clinical heterogeneity, frequent diagnostic delay and reliance of therapeutic trials on survival as the primary outcome measure make the discovery of biomarkers in ALS a research priority. Whilst the spinal anterior horns and corticospinal tract superfi cially appear to bear the brunt of histopathology in ALS, it has been clear for over half a century that degeneration extends to involve the extra-motor brain, preferentially involving areas of the frontal and temporal lobes having clinical and genetic overlap with some forms of frontotemporal dementia (FTD).

Original publication





Book title

Pet and Spect in Neurology

Publication Date



639 - 654